The herpes simplex virus (HSV) treatment sector is undergoing a remarkable transformation as biotechnology companies and pharmaceutical giants race to develop breakthrough therapies for this persistent viral infection. Affecting over 500 million people globally, HSV presents both significant medical challenges and substantial commercial opportunities that are reshaping...
English
Français
Español
Português
Deutsch
Türkçe
Nederlands
Italiano
Русский
Română
Português
Ελληνικά
Tiếng Việt